A study published in Nature Microbiology reported that the gut microbiome can modulate the efficacy and safety of Parkinson’s disease medications, highlighting drug–microbiome interactions as a clinically actionable variable. Researchers led by Verdegaal et al. described a complex interaction model in which specific microbiome features affect how co-prescribed therapies behave in patients. The findings add to the broader effort to understand why some patients see reduced benefit or different side-effect profiles when treated for neurodegenerative disease. For development teams, the work strengthens the rationale for incorporating microbiome profiling into clinical pharmacology programs. Next steps likely include identifying which microbial taxa or metabolic pathways drive the effect and whether microbiome-targeted interventions can standardize outcomes.